TABLE III.
Treatment patterns in the 2003–2006 and 2010–2011 cohorts
| Treatment variable | Cohort | |
|---|---|---|
|
| ||
| 2003–2006 (n=922) | 2010–2011 (n=560) | |
| Patients deemed to be candidates for CTx [n (%) of the cohort] | 324 (35) | 197 (35) |
| Patients who received ... | ||
| Systemic therapy (n) | 225 | 150 |
| As a percentage (%) of ... | ||
| Those referred to medical oncology | 44 | 52 |
| The cohort | 24 | 27 |
| First-line cytotoxic CTx (n) | 204 | 130 |
| As a percentage (%) of ... | ||
| Those referred to medical oncology | 40 | 46 |
| The cohort | 22 | 23 |
| Patients who received EGFR TKI [n (%) of the cohort] | 87 (9) | 42 (8) |
| Received both CTx and EGFR TKI (n) | 66 | 22 |
| Received EGFR TKI only (n) | 21 | 20 |
| Type of first-line cytotoxic CTx received [n (%) of those receiving first-line CTx] | ||
| Platinum doublet | 155 (76) | 102 (78) |
| Platinum doublet plus targeted agent | 20 (10) | 1 (1) |
| Non-platinum doublet | 6 (3) | 0 (0) |
| Platinum triplet | 1 (<1) | 1 (1) |
| Single agent | 11 (5) | 9 (7) |
| Single agent plus targeted agent | 3 (1) | 0 (0) |
| Other or unknown | 8 (4) | 17 (13) |
| Patients who required dose reduction or discontinuation because of toxicity [n (%)] | 46 of 204 (23) | 22 of 61 (36) |
| Patients who ... [n (%) of the cohort] | ||
| Received second-line systemic therapy | 37 (4) | 41 (7) |
| Received third-line systemic therapy | 7 (1) | 11 (2) |
| Received radiation therapy | 648 (71) | 291 (52) |
| Patients who enrolled in clinical trials [n (%) of the cohort] | 54 (6) | 9 (2) |
CTx = chemotherapy; EGFR = epidermal growth factor receptor; TKI = tyrosine kinase inhibitor.